<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">nnp</journal-id><journal-title-group><journal-title xml:lang="en">Neurology, Neuropsychiatry, Psychosomatics</journal-title><trans-title-group xml:lang="ru"><trans-title>Неврология, нейропсихиатрия, психосоматика</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2074-2711</issn><issn pub-type="epub">2310-1342</issn><publisher><publisher-name>"IMA-Press", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/2074-2711-2021-1S-62-68</article-id><article-id custom-type="elpub" pub-id-type="custom">nnp-1651</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group></article-categories><title-group><article-title>Influence of von Willebrand factor on common pathophysiological mechanisms of cerebrovascular diseases and multiple sclerosis</article-title><trans-title-group xml:lang="ru"><trans-title>Влияние фактора Виллебранда на общие патофизиологические механизмы цереброваскулярной патологии и рассеянного склероза</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кольцов</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Koltsov</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Иван Алексеевич Кольцов</p><p>отдел нейроиммунологии</p><p>117997, Москва, ул. Островитянова, 1117997, Москва, улица Островитянова, 1, стр. 10</p></bio><bio xml:lang="en"><p>Ivan Alekseevich Koltsov</p><p>Department of Neuroimmunology</p><p>1, Ostrovityanov St., Moscow 1179971, Ostrovityanov St., Build 10, Moscow 117997</p></bio><email xlink:type="simple">i-koltsov@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мартынов</surname><given-names>М. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Martynov</surname><given-names>M. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>отдел нейроиммунологии</p><p>117997, Москва, ул. Островитянова, 1117997, Москва, улица Островитянова, 1, стр. 10</p></bio><bio xml:lang="en"><p>Department of Neuroimmunology</p><p>1, Ostrovityanov St., Moscow 1179971, Ostrovityanov St., Build 10, Moscow 117997</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ясаманова</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Yasamanova</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>117997, Москва, ул. Островитянова, 1</p></bio><bio xml:lang="en"><p>1, Ostrovityanov St., Moscow 117997</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Щукин</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Shchukin</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>отдел нейроиммунологии</p><p>117997, Москва, ул. Островитянова, 1117997, Москва, улица Островитянова, 1, стр. 10</p></bio><bio xml:lang="en"><p>Department of Neuroimmunology</p><p>1, Ostrovityanov St., Moscow 1179971, Ostrovityanov St., Build 10, Moscow 117997</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фидлер</surname><given-names>М. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Fidler</surname><given-names>M. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>117997, Москва, ул. Островитянова, 1</p></bio><bio xml:lang="en"><p>1, Ostrovityanov St., Moscow 117997</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бойко</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Boyko</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>отдел нейроиммунологии</p><p>117997, Москва, ул. Островитянова, 1117997, Москва, улица Островитянова, 1, стр. 10</p></bio><bio xml:lang="en"><p>Department of Neuroimmunology</p><p>1, Ostrovityanov St., Moscow 1179971, Ostrovityanov St., Build 10, Moscow 117997</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России; ФГБУ «Федеральный центр мозга и нейротехнологий» ФМБА России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; Federal Center of Brain and Neurotechnologies, FMBA of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>16</day><month>09</month><year>2021</year></pub-date><volume>13</volume><issue>1S</issue><issue-title>Спецвыпуск: рассеянный склероз</issue-title><fpage>62</fpage><lpage>68</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Koltsov I.A., Martynov M.Y., Yasamanova A.N., Shchukin I.A., Fidler M.S., Boyko A.N., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Кольцов И.А., Мартынов М.Ю., Ясаманова А.Н., Щукин И.А., Фидлер М.С., Бойко А.Н.</copyright-holder><copyright-holder xml:lang="en">Koltsov I.A., Martynov M.Y., Yasamanova A.N., Shchukin I.A., Fidler M.S., Boyko A.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://nnp.ima-press.net/nnp/article/view/1651">https://nnp.ima-press.net/nnp/article/view/1651</self-uri><abstract><p>Endothelial dysfunction is a universal pathological mechanism underlying or contributing to the development/progression of many diseases, including cerebrovascular disease and multiple sclerosis. Von Willebrand factor is a multimeric glycoprotein synthesized by endothelial cells and megakaryocytes that participates in a range of physiological and pathological processes, including primary hemostasis and coagulation. It also regulates secretion and transport of a variety of molecules, exerts a proinflammatory effect, modulates angiogenesis and smooth muscle mitotic activity, influences atherogenesis. In this review, we discuss the synthesis, secretion, and regulation of the von Willebrand factor within the context of endothelial dysfunction and other common mechanisms that play a significant role in brain tissue damage in cerebrovascular diseases and multiple sclerosis.</p></abstract><trans-abstract xml:lang="ru"><p>Эндотелиальная дисфункция – универсальный патологический механизм, лежащий в основе или вносящий вклад в развитие/прогрессирование множества заболеваний, включая цереброваскулярные болезни и рассеянный склероз. Фактор Виллебранда – мультимерный гликопротеин, который синтезируется клетками эндотелия и мегакариоцитами и участвует в целом спектре физиологических и патологических процессов, в частности в сосудисто-тромбоцитарном и коагуляционном гемостазе, а также регулирует секрецию и транспортировку множества веществ, оказывает провоспалительный эффект, модулирует ангиогенез и митогенную активность гладкой мускулатуры сосудов, влияет на течение атеросклероза. В настоящем обзоре рассматриваются особенности образования, выделения, регуляции активности фактора Виллебранда во взаимосвязи с эндотелиальной дисфункцией и другими общими механизмами, играющими важную роль в повреждении вещества головного мозга при цереброваскулярной патологии и рассеянном склерозе.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>фактор Виллебранда</kwd><kwd>эндотелиальная дисфункция</kwd><kwd>цереброваскулярные заболевания</kwd><kwd>инсульт</kwd><kwd>рассеянный склероз</kwd></kwd-group><kwd-group xml:lang="en"><kwd>von Willebrand factor</kwd><kwd>endothelial dysfunction</kwd><kwd>cerebrovascular diseases</kwd><kwd>stroke</kwd><kwd>multiple sclerosis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Wannamethee SG, Whincup PH, Lennon L, et al. Fibrin D-Dimer, Tissue-Type Plasminogen Activator, von Willebrand Factor, and Risk of Incident Stroke in Older Men. Stroke. 2012;43(5):1206-11. doi: 10.1161/STROKEAHA.111.636373</mixed-citation><mixed-citation xml:lang="en">Wannamethee SG, Whincup PH, Lennon L, et al. Fibrin D-Dimer, Tissue-Type Plasminogen Activator, von Willebrand Factor, and Risk of Incident Stroke in Older Men. Stroke. 2012;43(5):1206-11. doi: 10.1161/STROKEAHA.111.636373</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Williams SR, Hsu F-C, Keene KL, et al. Genetic Drivers of von Willebrand Factor Levels in an Ischemic Stroke Population and Association With Risk for Recurrent Stroke. Stroke. 2017;48(6):1444-50. doi: 10.1161/STROKEAHA.116.015677</mixed-citation><mixed-citation xml:lang="en">Williams SR, Hsu F-C, Keene KL, et al. Genetic Drivers of von Willebrand Factor Levels in an Ischemic Stroke Population and Association With Risk for Recurrent Stroke. Stroke. 2017;48(6):1444-50. doi: 10.1161/STROKEAHA.116.015677</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Tzoulaki I, Murray GD, Lee AJ, et al. Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke – The Edinburgh Artery Study. Circulation. 2007;115(16):2119-27. doi: 10.1161/CIRCULATIONAHA.106.635029</mixed-citation><mixed-citation xml:lang="en">Tzoulaki I, Murray GD, Lee AJ, et al. Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke – The Edinburgh Artery Study. Circulation. 2007;115(16):2119-27. doi: 10.1161/CIRCULATIONAHA.106.635029</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Dubchenko E, Ivanov A, Spirina N, et al. Hyperhomocysteinemia and Endothelial Dysfunction in Multiple Sclerosis. Brain Sci. 2020;10(9):E637. doi: 10.3390/brain-sci10090637</mixed-citation><mixed-citation xml:lang="en">Dubchenko E, Ivanov A, Spirina N, et al. Hyperhomocysteinemia and Endothelial Dysfunction in Multiple Sclerosis. Brain Sci. 2020;10(9):E637. doi: 10.3390/brain-sci10090637</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Lenting PJ, Casari C, Christophe OD, Denis CV. Von Willebrand factor: the old, the new and the unknown. J Thromb Haemost. 2012;10(12):2428-37. doi: 10.1111/jth.12008</mixed-citation><mixed-citation xml:lang="en">Lenting PJ, Casari C, Christophe OD, Denis CV. Von Willebrand factor: the old, the new and the unknown. J Thromb Haemost. 2012;10(12):2428-37. doi: 10.1111/jth.12008</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998;67:395-424. doi: 10.1146/annurev.biochem.67.1.395</mixed-citation><mixed-citation xml:lang="en">Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998;67:395-424. doi: 10.1146/annurev.biochem.67.1.395</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Vischer UM. Von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost. 2006;4(6):1186-93. doi: 10.1111/j.1538-7836.2006.01949.x</mixed-citation><mixed-citation xml:lang="en">Vischer UM. Von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost. 2006;4(6):1186-93. doi: 10.1111/j.1538-7836.2006.01949.x</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Wagner D, Olmsted J, Marder V. Immunolocalization of Von-Willebrand Protein in Weibel-Palade Bodies of Human-Endothelial Cells. J Cell Biol. 1982;95(1):355-60. doi: 10.1083/jcb.95.1.355</mixed-citation><mixed-citation xml:lang="en">Wagner D, Olmsted J, Marder V. Immunolocalization of Von-Willebrand Protein in Weibel-Palade Bodies of Human-Endothelial Cells. J Cell Biol. 1982;95(1):355-60. doi: 10.1083/jcb.95.1.355</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Romani de Wit T, Rondaij MG, Hordijk PL, et al. Real-time imaging of the dynamics and secretory behavior of Weibel-Palade bodies. Arterioscler Thromb Vasc Biol. 2003;23(5):755-61. doi: 10.1161/01.ATV.0000069847.72001.E8</mixed-citation><mixed-citation xml:lang="en">Romani de Wit T, Rondaij MG, Hordijk PL, et al. Real-time imaging of the dynamics and secretory behavior of Weibel-Palade bodies. Arterioscler Thromb Vasc Biol. 2003;23(5):755-61. doi: 10.1161/01.ATV.0000069847.72001.E8</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Harrison P, Cramer E. Platelet Alpha-Granules. Blood Rev. 1993;7(1):52-62. doi: 10.1016/0268-960X(93)90024-X</mixed-citation><mixed-citation xml:lang="en">Harrison P, Cramer E. Platelet Alpha-Granules. Blood Rev. 1993;7(1):52-62. doi: 10.1016/0268-960X(93)90024-X</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Veljkovic DK, Cramer EM, Alimardani G, et al. Studies of alpha-granule proteins in cultured human megakaryocytes. Thromb Haemost. 2003;90(5):844-52. doi: 10.1160/TH03-02-0125</mixed-citation><mixed-citation xml:lang="en">Veljkovic DK, Cramer EM, Alimardani G, et al. Studies of alpha-granule proteins in cultured human megakaryocytes. Thromb Haemost. 2003;90(5):844-52. doi: 10.1160/TH03-02-0125</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Lenting PJ, Christophe OD, Denis CV. Von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. Blood. 2015;125(13):2019-28. doi: 10.1182/blood-2014-06-528406</mixed-citation><mixed-citation xml:lang="en">Lenting PJ, Christophe OD, Denis CV. Von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. Blood. 2015;125(13):2019-28. doi: 10.1182/blood-2014-06-528406</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Galbusera M, Zoja C, Donadelli R, et al. Fluid shear stress modulates von Willebrand factor release from human vascular endothelium. Blood. 1997;90(4):1558-64.</mixed-citation><mixed-citation xml:lang="en">Galbusera M, Zoja C, Donadelli R, et al. Fluid shear stress modulates von Willebrand factor release from human vascular endothelium. Blood. 1997;90(4):1558-64.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood. 2008;112(1):11-8. doi: 10.1182/blood-2008-02-078170</mixed-citation><mixed-citation xml:lang="en">Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood. 2008;112(1):11-8. doi: 10.1182/blood-2008-02-078170</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou WH, Inada M, Lee TP, et al. ADAMTS13 is expressed in hepatic stellate cells. Lab Invest. 2005;85(6):780-8. doi: 10.1038/labinvest.3700275</mixed-citation><mixed-citation xml:lang="en">Zhou WH, Inada M, Lee TP, et al. ADAMTS13 is expressed in hepatic stellate cells. Lab Invest. 2005;85(6):780-8. doi: 10.1038/labinvest.3700275</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Feys HB, Anderson PJ, Vanhoorelbeke K, et al. Multi-step binding of ADAMTS-13 to von Willebrand factor. J Thromb Haemost. 2009;7(12):2088-95. doi: 10.1111/j.1538-7836.2009.03620.x</mixed-citation><mixed-citation xml:lang="en">Feys HB, Anderson PJ, Vanhoorelbeke K, et al. Multi-step binding of ADAMTS-13 to von Willebrand factor. J Thromb Haemost. 2009;7(12):2088-95. doi: 10.1111/j.1538-7836.2009.03620.x</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Muia J, Zhu J, Gupta G, et al. Allosteric activation of ADAMTS13 by von Willebrand factor. Proc Natl Acad Sci U S A. 2014;111(52):18584-9. doi: 10.1073/pnas.1413282112</mixed-citation><mixed-citation xml:lang="en">Muia J, Zhu J, Gupta G, et al. Allosteric activation of ADAMTS13 by von Willebrand factor. Proc Natl Acad Sci U S A. 2014;111(52):18584-9. doi: 10.1073/pnas.1413282112</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Song J, Chen F, Campos M, et al. Quantitative Influence of ABO Blood Groups on Factor VIII and Its Ratio to von Willebrand Factor, Novel Observations from an ARIC Study of 11,673 Subjects. Plos One. 2015;10(8):e0132626. doi: 10.1371/journal.pone.0132626</mixed-citation><mixed-citation xml:lang="en">Song J, Chen F, Campos M, et al. Quantitative Influence of ABO Blood Groups on Factor VIII and Its Ratio to von Willebrand Factor, Novel Observations from an ARIC Study of 11,673 Subjects. Plos One. 2015;10(8):e0132626. doi: 10.1371/journal.pone.0132626</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Konkle BA. Von Willebrand Factor and Aging. Semin Thromb Hemost. 2014;40(6):640-4. doi: 10.1055/s-0034-1389079</mixed-citation><mixed-citation xml:lang="en">Konkle BA. Von Willebrand Factor and Aging. Semin Thromb Hemost. 2014;40(6):640-4. doi: 10.1055/s-0034-1389079</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Kokame K, Sakata T, Kokubo Y, Miyata T. Von Willebrand factor-to-ADAMTS13 ratio increases with age in a Japanese population. J Thromb Haemost. 2011;9(7):1426-8. doi: 10.1111/j.1538-7836.2011.04333.x</mixed-citation><mixed-citation xml:lang="en">Kokame K, Sakata T, Kokubo Y, Miyata T. Von Willebrand factor-to-ADAMTS13 ratio increases with age in a Japanese population. J Thromb Haemost. 2011;9(7):1426-8. doi: 10.1111/j.1538-7836.2011.04333.x</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Inoue O, Suzuki-Inoue K, Ozaki Y. Redundant mechanism of platelet adhesion to laminin and collagen under flow – Involvement of von Willebrand factor and glycoprotein Ib-IX-V. J Biol Chem. 2008;283(24):16279-82. doi: 10.1074/jbc.C700241200</mixed-citation><mixed-citation xml:lang="en">Inoue O, Suzuki-Inoue K, Ozaki Y. Redundant mechanism of platelet adhesion to laminin and collagen under flow – Involvement of von Willebrand factor and glycoprotein Ib-IX-V. J Biol Chem. 2008;283(24):16279-82. doi: 10.1074/jbc.C700241200</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Rauch A, Wohner N, Christophe OD, et al. On the Versatility of von Willebrand Factor. Mediterr J Hematol Infect Dis. 2013;5(1):e2013046. doi: 10.4084/MJHID.2013.046</mixed-citation><mixed-citation xml:lang="en">Rauch A, Wohner N, Christophe OD, et al. On the Versatility of von Willebrand Factor. Mediterr J Hematol Infect Dis. 2013;5(1):e2013046. doi: 10.4084/MJHID.2013.046</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Bendetowicz AV, Wise RJ, Gilbert GE. Collagen-bound von Willebrand factor has reduced affinity for factor VIII. J Biol Chem. 1999;274(18):12300-7. doi: 10.1074/jbc.274.18.12300</mixed-citation><mixed-citation xml:lang="en">Bendetowicz AV, Wise RJ, Gilbert GE. Collagen-bound von Willebrand factor has reduced affinity for factor VIII. J Biol Chem. 1999;274(18):12300-7. doi: 10.1074/jbc.274.18.12300</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Keuren JFW, Magdeleyns EJP, Bennaghmouch A, et al. Microparticles adhere to collagen type I, fibrinogen, von Willebrand factor and surface immobilised platelets at physiological shear rates. Br J Haematol. 2007;138(4):527-33. doi: 10.1111/j.1365-2141.2007.06650.x</mixed-citation><mixed-citation xml:lang="en">Keuren JFW, Magdeleyns EJP, Bennaghmouch A, et al. Microparticles adhere to collagen type I, fibrinogen, von Willebrand factor and surface immobilised platelets at physiological shear rates. Br J Haematol. 2007;138(4):527-33. doi: 10.1111/j.1365-2141.2007.06650.x</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Reininger AJ. Platelet function under high shear conditions. Hämostaseologie. 2009;29(1):21-4. doi: 10.1055/s-0037-1616934</mixed-citation><mixed-citation xml:lang="en">Reininger AJ. Platelet function under high shear conditions. Hämostaseologie. 2009;29(1):21-4. doi: 10.1055/s-0037-1616934</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Chen Y, Xiao Y, Lin Z, et al. The Role of Circulating Platelets Microparticles and Platelet Parameters in Acute Ischemic Stroke Patients. J Stroke Cerebrovasc Dis. 2015;24(10):2313-20. doi: 10.1016/j.jstroke-cerebrovasdis.2015.06.018</mixed-citation><mixed-citation xml:lang="en">Chen Y, Xiao Y, Lin Z, et al. The Role of Circulating Platelets Microparticles and Platelet Parameters in Acute Ischemic Stroke Patients. J Stroke Cerebrovasc Dis. 2015;24(10):2313-20. doi: 10.1016/j.jstroke-cerebrovasdis.2015.06.018</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Huang M, Hu Y-Y, Dong X-Q. High concentrations of procoagulant microparticles in the cerebrospinal fluid and peripheral blood of patients with acute basal ganglia hemorrhage are associated with poor outcome. Surg Neurol. 2009;72(5):481-9. doi: 10.1016/j.surneu.2008.12.016</mixed-citation><mixed-citation xml:lang="en">Huang M, Hu Y-Y, Dong X-Q. High concentrations of procoagulant microparticles in the cerebrospinal fluid and peripheral blood of patients with acute basal ganglia hemorrhage are associated with poor outcome. Surg Neurol. 2009;72(5):481-9. doi: 10.1016/j.surneu.2008.12.016</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Marcos-Ramiro B, Oliva Nacarino P, Serrano-Pertierra E, et al. Microparticles in multiple sclerosis and clinically isolated syndrome: effect on endothelial barrier function. BMC Neurosci. 2014;15:110. doi: 10.1186/1471-2202-15-110</mixed-citation><mixed-citation xml:lang="en">Marcos-Ramiro B, Oliva Nacarino P, Serrano-Pertierra E, et al. Microparticles in multiple sclerosis and clinically isolated syndrome: effect on endothelial barrier function. BMC Neurosci. 2014;15:110. doi: 10.1186/1471-2202-15-110</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Jy W, Jimenez JJ, Mauro LM, et al. Endothelial microparticles induce formation of platelet aggregates via a von Willebrand factor/ristocetin dependent pathway, rendering them resistant to dissociation. J Thromb Haemost. 2005;3(6):1301-8. doi: 10.1111/j.1538-7836.2005.01384.x</mixed-citation><mixed-citation xml:lang="en">Jy W, Jimenez JJ, Mauro LM, et al. Endothelial microparticles induce formation of platelet aggregates via a von Willebrand factor/ristocetin dependent pathway, rendering them resistant to dissociation. J Thromb Haemost. 2005;3(6):1301-8. doi: 10.1111/j.1538-7836.2005.01384.x</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Scharpfenecker M, Fiedler U, Reiss Y, Augustin HG. The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci. 2005;118(4):771-80. doi: 10.1242/jcs.01653</mixed-citation><mixed-citation xml:lang="en">Scharpfenecker M, Fiedler U, Reiss Y, Augustin HG. The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci. 2005;118(4):771-80. doi: 10.1242/jcs.01653</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Starke RD, Ferraro F, Paschalaki KE, et al. Endothelial von Willebrand factor regulates angiogenesis. Blood. 2011;117(3):1071-80. doi: 10.1182/blood-2010-01-264507</mixed-citation><mixed-citation xml:lang="en">Starke RD, Ferraro F, Paschalaki KE, et al. Endothelial von Willebrand factor regulates angiogenesis. Blood. 2011;117(3):1071-80. doi: 10.1182/blood-2010-01-264507</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Li Z, Korhonen EA, Merlini A, et al. Angiopoietin-2 blockade ameliorates autoimmune neuroinflammation by inhibiting leukocyte recruitment into the CNS. J Clin Invest. 2020;130(4):1977-90. doi: 10.1172/JCI130308</mixed-citation><mixed-citation xml:lang="en">Li Z, Korhonen EA, Merlini A, et al. Angiopoietin-2 blockade ameliorates autoimmune neuroinflammation by inhibiting leukocyte recruitment into the CNS. J Clin Invest. 2020;130(4):1977-90. doi: 10.1172/JCI130308</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Qin F, Impeduglia T, Schaffer P, Dardik H. Overexpression of von Willebrand factor is an independent risk factor for pathogenesis of intimal hyperplasia: Preliminary studies. J Vasc Surg. 2003;37(2):433-9. doi: 10.1067/mva.2003.63</mixed-citation><mixed-citation xml:lang="en">Qin F, Impeduglia T, Schaffer P, Dardik H. Overexpression of von Willebrand factor is an independent risk factor for pathogenesis of intimal hyperplasia: Preliminary studies. J Vasc Surg. 2003;37(2):433-9. doi: 10.1067/mva.2003.63</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang X, Meng H, Blaivas M, et al. Von Willebrand Factor Permeates Small Vessels in CADASIL and Inhibits Smooth Muscle Gene Expression. Transl Stroke Res. 2012;3(1):138-45. doi: 10.1007/s12975-011-0112-2</mixed-citation><mixed-citation xml:lang="en">Zhang X, Meng H, Blaivas M, et al. Von Willebrand Factor Permeates Small Vessels in CADASIL and Inhibits Smooth Muscle Gene Expression. Transl Stroke Res. 2012;3(1):138-45. doi: 10.1007/s12975-011-0112-2</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Michaux G, Pullen TJ, Haberichter SL, Cutler DF. P-selectin binds to the D'-D3 domains of von Willebrand factor in WeibelPalade bodies. Blood. 2006;107(10):3922-4. doi: 10.1182/blood-2005-09-3635</mixed-citation><mixed-citation xml:lang="en">Michaux G, Pullen TJ, Haberichter SL, Cutler DF. P-selectin binds to the D'-D3 domains of von Willebrand factor in WeibelPalade bodies. Blood. 2006;107(10):3922-4. doi: 10.1182/blood-2005-09-3635</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Denis CV, Andre P, Saffaripour S, Wagner DD. Defect in regulated secretion of P-selectin affects leukocyte recruitment in von Willebrand factor-deficient mice. Proc Natl Acad Sci USA. 2001;98(7):4072-7. doi: 10.1073/pnas.061307098</mixed-citation><mixed-citation xml:lang="en">Denis CV, Andre P, Saffaripour S, Wagner DD. Defect in regulated secretion of P-selectin affects leukocyte recruitment in von Willebrand factor-deficient mice. Proc Natl Acad Sci USA. 2001;98(7):4072-7. doi: 10.1073/pnas.061307098</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Gragnano F, Sperlongano S, Golia E, et al. The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy. Mediators Inflamm. 2017;2017:5620314. doi: 10.1155/2017/5620314</mixed-citation><mixed-citation xml:lang="en">Gragnano F, Sperlongano S, Golia E, et al. The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy. Mediators Inflamm. 2017;2017:5620314. doi: 10.1155/2017/5620314</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Khan MM, Motto DG, Lentz SR, Chauhan AK. ADAMTS13 reduces VWF-mediated acute inflammation following focal cerebral ischemia in mice. J Thromb Haemost. 2012;10(8):1665-71. doi: 10.1111/j.1538-7836.2012.04822.x</mixed-citation><mixed-citation xml:lang="en">Khan MM, Motto DG, Lentz SR, Chauhan AK. ADAMTS13 reduces VWF-mediated acute inflammation following focal cerebral ischemia in mice. J Thromb Haemost. 2012;10(8):1665-71. doi: 10.1111/j.1538-7836.2012.04822.x</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Pendu R, Terraube V, Christophe OD, et al. P-selectin glycoprotein ligand 1 and beta 2integrins cooperate in the adhesion of leukocytes to von Willebrand factor. Blood. 2006;108(12):3746-52. doi: 10.1182/blood-2006-03-010322</mixed-citation><mixed-citation xml:lang="en">Pendu R, Terraube V, Christophe OD, et al. P-selectin glycoprotein ligand 1 and beta 2integrins cooperate in the adhesion of leukocytes to von Willebrand factor. Blood. 2006;108(12):3746-52. doi: 10.1182/blood-2006-03-010322</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Fuchs TA, Brill A, Duerschmied D, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA. 2010;107(36):15880-5. doi: 10.1073/pnas.1005743107</mixed-citation><mixed-citation xml:lang="en">Fuchs TA, Brill A, Duerschmied D, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA. 2010;107(36):15880-5. doi: 10.1073/pnas.1005743107</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Rondaij MG, Bierings R, Kragt A, et al. Dynamics and Plasticity of Weibel-Palade Bodies in Endothelial Cells. Arterioscler Thromb Vasc Biol. 2006;26(5):1002-7. doi: 10.1161/01.ATV.0000209501.56852.6c</mixed-citation><mixed-citation xml:lang="en">Rondaij MG, Bierings R, Kragt A, et al. Dynamics and Plasticity of Weibel-Palade Bodies in Endothelial Cells. Arterioscler Thromb Vasc Biol. 2006;26(5):1002-7. doi: 10.1161/01.ATV.0000209501.56852.6c</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Bierings R, van den Biggelaar M, Kragt A, et al. Efficiency of von Willebrand factor-mediated targeting of interleukin-8 into Weibel-Palade bodies. J Thromb Haemost. 2007;5(12):2512-9. doi: 10.1111/j.1538-7836.2007.02768.x</mixed-citation><mixed-citation xml:lang="en">Bierings R, van den Biggelaar M, Kragt A, et al. Efficiency of von Willebrand factor-mediated targeting of interleukin-8 into Weibel-Palade bodies. J Thromb Haemost. 2007;5(12):2512-9. doi: 10.1111/j.1538-7836.2007.02768.x</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Bernardo A, Ball C, Nolasco L, et al. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood. 2004;104(1):100-6. doi: 10.1182/blood-2004-01-0107</mixed-citation><mixed-citation xml:lang="en">Bernardo A, Ball C, Nolasco L, et al. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood. 2004;104(1):100-6. doi: 10.1182/blood-2004-01-0107</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Knipe L, Meli A, Hewlett L, et al. A revised model for the secretion of tPA and cytokines from cultured endothelial cells. Blood. 2010;116(12):2183-91. doi: 10.1182/blood-2010-03-276170</mixed-citation><mixed-citation xml:lang="en">Knipe L, Meli A, Hewlett L, et al. A revised model for the secretion of tPA and cytokines from cultured endothelial cells. Blood. 2010;116(12):2183-91. doi: 10.1182/blood-2010-03-276170</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Arumugam TV, Woodruff TM, Lathia JD, et al. Neuroprotection in Stroke by Complement Inhibition and Immunoglobulin Therapy. Neuroscience. 2009;158(3):1074-89. doi: 10.1016/j.neuro-science.2008.07.015</mixed-citation><mixed-citation xml:lang="en">Arumugam TV, Woodruff TM, Lathia JD, et al. Neuroprotection in Stroke by Complement Inhibition and Immunoglobulin Therapy. Neuroscience. 2009;158(3):1074-89. doi: 10.1016/j.neuro-science.2008.07.015</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Turner NA, Moake J. Assembly and Activation of Alternative Complement Components on Endothelial Cell-Anchored Ultra-Large Von Willebrand Factor Links Complement and Hemostasis-Thrombosis. Plos One. 2013;8(3):e59372. doi: 10.1371/journal.pone.0059372</mixed-citation><mixed-citation xml:lang="en">Turner NA, Moake J. Assembly and Activation of Alternative Complement Components on Endothelial Cell-Anchored Ultra-Large Von Willebrand Factor Links Complement and Hemostasis-Thrombosis. Plos One. 2013;8(3):e59372. doi: 10.1371/journal.pone.0059372</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Feng S, Liang X, Cruz MA, et al. The Interaction between Factor H and Von Willebrand Factor. Plos One. 2013;8(8):e73715. doi: 10.1371/journal.pone.0073715</mixed-citation><mixed-citation xml:lang="en">Feng S, Liang X, Cruz MA, et al. The Interaction between Factor H and Von Willebrand Factor. Plos One. 2013;8(8):e73715. doi: 10.1371/journal.pone.0073715</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Feng S, Liang X, Kroll MH, et al. Von Willebrand factor is a cofactor in complement regulation. Blood. 2015;125(6):1034-7. doi: 10.1182/blood-2014-06-585430</mixed-citation><mixed-citation xml:lang="en">Feng S, Liang X, Kroll MH, et al. Von Willebrand factor is a cofactor in complement regulation. Blood. 2015;125(6):1034-7. doi: 10.1182/blood-2014-06-585430</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Ingram G, Hakobyan S, Robertson NP, Morgan BP. Complement in multiple sclerosis: its role in disease and potential as a biomarker. Clin Exp Immunol. 2009;155(2):128-39. doi: 10.1111/j.1365-2249.2008.03830.x</mixed-citation><mixed-citation xml:lang="en">Ingram G, Hakobyan S, Robertson NP, Morgan BP. Complement in multiple sclerosis: its role in disease and potential as a biomarker. Clin Exp Immunol. 2009;155(2):128-39. doi: 10.1111/j.1365-2249.2008.03830.x</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Zagorac D, Yamaura K, Zhang C, et al. The effect of superoxide anion on autoregulation of cerebral blood flow. Stroke. 2005;36(12):2589-94. doi: 10.1161/01.STR.0000189997.84161.95</mixed-citation><mixed-citation xml:lang="en">Zagorac D, Yamaura K, Zhang C, et al. The effect of superoxide anion on autoregulation of cerebral blood flow. Stroke. 2005;36(12):2589-94. doi: 10.1161/01.STR.0000189997.84161.95</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Chen B, Cheng Q, Yang K, Lyden PD. Thrombin Mediates Severe Neurovascular Injury During Ischemia. Stroke. 2010;41(10):2348-52. doi: 10.1161/STROKEAHA.110.584920</mixed-citation><mixed-citation xml:lang="en">Chen B, Cheng Q, Yang K, Lyden PD. Thrombin Mediates Severe Neurovascular Injury During Ischemia. Stroke. 2010;41(10):2348-52. doi: 10.1161/STROKEAHA.110.584920</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Sonneveld MAH, Franco OH, Ikram MA, et al. Von Willebrand Factor, ADAMTS13, and the Risk of Mortality – The Rotterdam Study. Arterioscler Thromb Vasc Biol. 2016;36(12):2446-51. doi: 10.1161/ATVBAHA.116.308225</mixed-citation><mixed-citation xml:lang="en">Sonneveld MAH, Franco OH, Ikram MA, et al. Von Willebrand Factor, ADAMTS13, and the Risk of Mortality – The Rotterdam Study. Arterioscler Thromb Vasc Biol. 2016;36(12):2446-51. doi: 10.1161/ATVBAHA.116.308225</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Wieberdink RG, van Schie MC, Koudstaal PJ, et al. High von Willebrand Factor Levels Increase the Risk of Stroke – The Rotterdam Study. Stroke. 2010;41(10):2151-6. doi: 10.1161/STROKEAHA.110.586289</mixed-citation><mixed-citation xml:lang="en">Wieberdink RG, van Schie MC, Koudstaal PJ, et al. High von Willebrand Factor Levels Increase the Risk of Stroke – The Rotterdam Study. Stroke. 2010;41(10):2151-6. doi: 10.1161/STROKEAHA.110.586289</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Sonneveld MAH, de Maat MPM, Portegies MLP, et al. Low ADAMTS13 activity is associated with an increased risk of ischemic stroke. Blood. 2015;126(25):2739-46. doi: 10.1182/blood-2015-05643338</mixed-citation><mixed-citation xml:lang="en">Sonneveld MAH, de Maat MPM, Portegies MLP, et al. Low ADAMTS13 activity is associated with an increased risk of ischemic stroke. Blood. 2015;126(25):2739-46. doi: 10.1182/blood-2015-05643338</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Blann AD, Naqvi T, Waite M, Mccollum CN. Von Willebrand factor and endothelial damage in essential hypertension. J Hum Hypertens. 1993;7(2):107-11.</mixed-citation><mixed-citation xml:lang="en">Blann AD, Naqvi T, Waite M, Mccollum CN. Von Willebrand factor and endothelial damage in essential hypertension. J Hum Hypertens. 1993;7(2):107-11.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Brandes RP. Endothelial Dysfunction and Hypertension. Hypertension. 2014;64(5):924-8. doi: 10.1161/HYPERTENSIONAHA.114.03575</mixed-citation><mixed-citation xml:lang="en">Brandes RP. Endothelial Dysfunction and Hypertension. Hypertension. 2014;64(5):924-8. doi: 10.1161/HYPERTENSIONAHA.114.03575</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Frankel DS, Meigs JB, Massaro JM, et al. Von Willebrand Factor, Type 2 Diabetes and Risk of Cardiovascular Disease: The Framingham Offspring Study. Circulation. 2008;118(24):2533-9. doi: 10.1161/CIRCULATIONAHA.108.792986</mixed-citation><mixed-citation xml:lang="en">Frankel DS, Meigs JB, Massaro JM, et al. Von Willebrand Factor, Type 2 Diabetes and Risk of Cardiovascular Disease: The Framingham Offspring Study. Circulation. 2008;118(24):2533-9. doi: 10.1161/CIRCULATIONAHA.108.792986</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Van Galen KPM, Tuinenburg A, Smeets EM, Schutgens REG. Von Willebrand factor deficiency and atherosclerosis. Blood Rev. 2012;26(5):189-96. doi: 10.1016/j.blre.2012.05.002</mixed-citation><mixed-citation xml:lang="en">Van Galen KPM, Tuinenburg A, Smeets EM, Schutgens REG. Von Willebrand factor deficiency and atherosclerosis. Blood Rev. 2012;26(5):189-96. doi: 10.1016/j.blre.2012.05.002</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Gandhi C, Ahmad A, Wilson KM, Chauhan AK. ADAMTS13 modulates atherosclerotic plaque progression in mice via a VWF-dependent mechanism. J Thromb Haemost. 2014;12(2):255-60. doi: 10.1111/jth.12456</mixed-citation><mixed-citation xml:lang="en">Gandhi C, Ahmad A, Wilson KM, Chauhan AK. ADAMTS13 modulates atherosclerotic plaque progression in mice via a VWF-dependent mechanism. J Thromb Haemost. 2014;12(2):255-60. doi: 10.1111/jth.12456</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Sonneveld MAH, van Dijk AC, van den Herik EG, et al. Relationship of Von Willebrand Factor with carotid artery and aortic arch calcification in ischemic stroke patients. Atherosclerosis. 2013;230(2):210-5. doi: 10.1016/j.atherosclerosis.2013.07.046</mixed-citation><mixed-citation xml:lang="en">Sonneveld MAH, van Dijk AC, van den Herik EG, et al. Relationship of Von Willebrand Factor with carotid artery and aortic arch calcification in ischemic stroke patients. Atherosclerosis. 2013;230(2):210-5. doi: 10.1016/j.atherosclerosis.2013.07.046</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Malek AM, Alper SL, Izumo S. Hemodynamic shear stress and its role in atherosclerosis. Jama-J Am Med Assoc. 1999;282(21):2035-42. doi: 10.1001/jama.282.21.2035</mixed-citation><mixed-citation xml:lang="en">Malek AM, Alper SL, Izumo S. Hemodynamic shear stress and its role in atherosclerosis. Jama-J Am Med Assoc. 1999;282(21):2035-42. doi: 10.1001/jama.282.21.2035</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Van Agtmaal EL, Bierings R, Dragt BS, et al. The Shear Stress-Induced Transcription Factor KLF2 Affects Dynamics and Angiopoietin-2 Content of Weibel-Palade Bodies. Plos One. 2012;7(6):e38399. doi: 10.1371/journal.pone.0038399</mixed-citation><mixed-citation xml:lang="en">Van Agtmaal EL, Bierings R, Dragt BS, et al. The Shear Stress-Induced Transcription Factor KLF2 Affects Dynamics and Angiopoietin-2 Content of Weibel-Palade Bodies. Plos One. 2012;7(6):e38399. doi: 10.1371/journal.pone.0038399</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Van Thienen JV, Fledderus JO, Dekker RJ, et al. Shear stress sustains atheroprotective endothelial KLF2 expression more potently than statins through mRNA stabilization. Cardiovasc Res. 2006;72(2):231-40. doi: 10.1016/j.cardiores.2006.07.008</mixed-citation><mixed-citation xml:lang="en">Van Thienen JV, Fledderus JO, Dekker RJ, et al. Shear stress sustains atheroprotective endothelial KLF2 expression more potently than statins through mRNA stabilization. Cardiovasc Res. 2006;72(2):231-40. doi: 10.1016/j.cardiores.2006.07.008</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Scridon A, Girerd N, Rugeri L, et al. Progressive endothelial damage revealed by multilevel von Willebrand factor plasma concentrations in atrial fibrillation patients. Europace. 2013;15(11):1562-6. doi: 10.1093/europace/eut121</mixed-citation><mixed-citation xml:lang="en">Scridon A, Girerd N, Rugeri L, et al. Progressive endothelial damage revealed by multilevel von Willebrand factor plasma concentrations in atrial fibrillation patients. Europace. 2013;15(11):1562-6. doi: 10.1093/europace/eut121</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Conway DSG, Pearce LA, Chin BSP, et al. Plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation – Relationship to stroke risk factors. Circulation. 2002;106(15):1962-7. doi: 10.1161/01.CIR.0000033220.97592.9A</mixed-citation><mixed-citation xml:lang="en">Conway DSG, Pearce LA, Chin BSP, et al. Plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation – Relationship to stroke risk factors. Circulation. 2002;106(15):1962-7. doi: 10.1161/01.CIR.0000033220.97592.9A</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Cortes GM, Sandoval MEV, Martinez CAA, et al. Von Willebrand Factor plasma levels variability in nonvalvular Atrial Fibrillation. J Atr Fibrillation. 2014;7(4):99-105. doi: 10.4022/jafib.1124</mixed-citation><mixed-citation xml:lang="en">Cortes GM, Sandoval MEV, Martinez CAA, et al. Von Willebrand Factor plasma levels variability in nonvalvular Atrial Fibrillation. J Atr Fibrillation. 2014;7(4):99-105. doi: 10.4022/jafib.1124</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Rewiuk K, Grodzicki T. Correlations of C-reactive protein, von Willebrand factor, and carotid artery intima-media thickness with CHA2DS2-VASc in patients with acute atrial fibrillation. Pol Arch Med Wewn. 2015;125(11):835-44. doi: 10.20452/pamw.3162</mixed-citation><mixed-citation xml:lang="en">Rewiuk K, Grodzicki T. Correlations of C-reactive protein, von Willebrand factor, and carotid artery intima-media thickness with CHA2DS2-VASc in patients with acute atrial fibrillation. Pol Arch Med Wewn. 2015;125(11):835-44. doi: 10.20452/pamw.3162</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Kraft P, Drechsler C, Gunreben I, et al. Von Willebrand Factor Regulation in Patients with Acute and Chronic Cerebrovascular Disease: A Pilot, Case-Control Study. Plos One. 2014;9(6):e99851. doi: 10.1371/journal.pone.0099851</mixed-citation><mixed-citation xml:lang="en">Kraft P, Drechsler C, Gunreben I, et al. Von Willebrand Factor Regulation in Patients with Acute and Chronic Cerebrovascular Disease: A Pilot, Case-Control Study. Plos One. 2014;9(6):e99851. doi: 10.1371/journal.pone.0099851</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Lynch JR, Blessing R, White WD, et al. Novel diagnostic test for acute stroke. Stroke. 2004;35(1):57-63. doi: 10.1161/01.STR.0000105927.62344.4C</mixed-citation><mixed-citation xml:lang="en">Lynch JR, Blessing R, White WD, et al. Novel diagnostic test for acute stroke. Stroke. 2004;35(1):57-63. doi: 10.1161/01.STR.0000105927.62344.4C</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Samai A, Monlezun D, Shaban A, et al. Von Willebrand Factor Drives the Association Between Elevated Factor VIII and Poor Outcomes in Patients With Ischemic Stroke. Stroke. 2014;45(9):2789-91. doi: 10.1161/STROKEAHA.114.006394</mixed-citation><mixed-citation xml:lang="en">Samai A, Monlezun D, Shaban A, et al. Von Willebrand Factor Drives the Association Between Elevated Factor VIII and Poor Outcomes in Patients With Ischemic Stroke. Stroke. 2014;45(9):2789-91. doi: 10.1161/STROKEAHA.114.006394</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Hanson E, Jood K, Karlsson S, et al. Plasma levels of von Willebrand factor in the etiologic subtypes of ischemic stroke. J Thromb Haemost. 2011;9(2):275-81. doi: 10.1111/j.1538-7836.2010.04134.x</mixed-citation><mixed-citation xml:lang="en">Hanson E, Jood K, Karlsson S, et al. Plasma levels of von Willebrand factor in the etiologic subtypes of ischemic stroke. J Thromb Haemost. 2011;9(2):275-81. doi: 10.1111/j.1538-7836.2010.04134.x</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Tobin WO, Kinsella JA, Kavanagh GF, et al. Profile of von Willebrand factor antigen and von Willebrand factor propeptide in an overall TIA and ischaemic stroke population and amongst subtypes. J Neurol Sci. 2017;375:404-10. doi: 10.1016/j.jns.2017.02.045</mixed-citation><mixed-citation xml:lang="en">Tobin WO, Kinsella JA, Kavanagh GF, et al. Profile of von Willebrand factor antigen and von Willebrand factor propeptide in an overall TIA and ischaemic stroke population and amongst subtypes. J Neurol Sci. 2017;375:404-10. doi: 10.1016/j.jns.2017.02.045</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Wiseman S, Marlborough F, Doubal F, et al. Blood Markers of Coagulation, Fibrinolysis, Endothelial Dysfunction and Inflammation in Lacunar Stroke versus Non-Lacunar Stroke and Non-Stroke: Systematic Review and Meta-Analysis. Cerebrovasc Dis. 2014;37(1):64-75. doi: 10.1159/000356789</mixed-citation><mixed-citation xml:lang="en">Wiseman S, Marlborough F, Doubal F, et al. Blood Markers of Coagulation, Fibrinolysis, Endothelial Dysfunction and Inflammation in Lacunar Stroke versus Non-Lacunar Stroke and Non-Stroke: Systematic Review and Meta-Analysis. Cerebrovasc Dis. 2014;37(1):64-75. doi: 10.1159/000356789</mixed-citation></citation-alternatives></ref><ref id="cit74"><label>74</label><citation-alternatives><mixed-citation xml:lang="ru">De Meyer SF, Stoll G, Wagner DD, Kleinschnitz C. Von Willebrand Factor an Emerging Target in Stroke Therapy. Stroke. 2012;43(2):599-606. doi: 10.1161/STROKEAHA.111.628867</mixed-citation><mixed-citation xml:lang="en">De Meyer SF, Stoll G, Wagner DD, Kleinschnitz C. Von Willebrand Factor an Emerging Target in Stroke Therapy. Stroke. 2012;43(2):599-606. doi: 10.1161/STROKEAHA.111.628867</mixed-citation></citation-alternatives></ref><ref id="cit75"><label>75</label><citation-alternatives><mixed-citation xml:lang="ru">McCabe DJH, Murphy SJX, Starke R, et al. Relationship between ADAMTS13 activity, von Willebrand factor antigen levels and platelet function in the early and late phases after TIA or ischaemic stroke. J Neurol Sci. 2015;348 (1-2):35-40. doi: 10.1016/j.jns.2014.10.035</mixed-citation><mixed-citation xml:lang="en">McCabe DJH, Murphy SJX, Starke R, et al. Relationship between ADAMTS13 activity, von Willebrand factor antigen levels and platelet function in the early and late phases after TIA or ischaemic stroke. J Neurol Sci. 2015;348 (1-2):35-40. doi: 10.1016/j.jns.2014.10.035</mixed-citation></citation-alternatives></ref><ref id="cit76"><label>76</label><citation-alternatives><mixed-citation xml:lang="ru">Lambers M, Goldenberg NA, Kenet G, et al. Role of Reduced ADAMTS13 in Arterial Ischemic Stroke: A Pediatric Cohort Study. Ann Neurol. 2013;73(1):58-64. doi: 10.1002/ana.23735</mixed-citation><mixed-citation xml:lang="en">Lambers M, Goldenberg NA, Kenet G, et al. Role of Reduced ADAMTS13 in Arterial Ischemic Stroke: A Pediatric Cohort Study. Ann Neurol. 2013;73(1):58-64. doi: 10.1002/ana.23735</mixed-citation></citation-alternatives></ref><ref id="cit77"><label>77</label><citation-alternatives><mixed-citation xml:lang="ru">Stoll M, Ruehle F, Witten A, et al. Rare Variants in the ADAMTS13 Von Willebrand Factor-Binding Domain Contribute to Pediatric Stroke. Circ-Cardiovasc Genet. 2016;9(4):357-67. doi: 10.1161/CIRCGENETICS.115.001184</mixed-citation><mixed-citation xml:lang="en">Stoll M, Ruehle F, Witten A, et al. Rare Variants in the ADAMTS13 Von Willebrand Factor-Binding Domain Contribute to Pediatric Stroke. Circ-Cardiovasc Genet. 2016;9(4):357-67. doi: 10.1161/CIRCGENETICS.115.001184</mixed-citation></citation-alternatives></ref><ref id="cit78"><label>78</label><citation-alternatives><mixed-citation xml:lang="ru">Bath PMW, Blann A, Smith N, Butterworth RJ. Von Willebrand factor, P-selectin and fibrinogen levels in patients with acute ischaemic and haemorrhagic stroke, and their relationship with stroke sub-type and functional outcome. Platelets. 1998;9(3-4):155-9. doi: 10.1080/09537109876618</mixed-citation><mixed-citation xml:lang="en">Bath PMW, Blann A, Smith N, Butterworth RJ. Von Willebrand factor, P-selectin and fibrinogen levels in patients with acute ischaemic and haemorrhagic stroke, and their relationship with stroke sub-type and functional outcome. Platelets. 1998;9(3-4):155-9. doi: 10.1080/09537109876618</mixed-citation></citation-alternatives></ref><ref id="cit79"><label>79</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu X, Cao Y, Wei L, et al. Von Willebrand factor contributes to poor outcome in a mouse model of intracerebral haemorrhage. Sci Rep. 2016;6:35901. doi: 10.1038/srep35901</mixed-citation><mixed-citation xml:lang="en">Zhu X, Cao Y, Wei L, et al. Von Willebrand factor contributes to poor outcome in a mouse model of intracerebral haemorrhage. Sci Rep. 2016;6:35901. doi: 10.1038/srep35901</mixed-citation></citation-alternatives></ref><ref id="cit80"><label>80</label><citation-alternatives><mixed-citation xml:lang="ru">Гусев ЕИ, Мартынов МЮ, Кольцов ИА и др. Прогностическое значение дисфункции эндотелия и фактора фон Виллебранда в остром и отдаленном периодах геморрагического инсульта полушарной локализации. Журнал неврологии и психиатрии им. C.С. Корсакова. 2019;119(8-2):46-52. doi: 10.17116/jnevro201911908246</mixed-citation><mixed-citation xml:lang="en">Gusev EI, Martynov MYu, Koltsov IA, et al. Prognostic value of endothelial dysfunction and von Willebrand factor in acute and chronic hemispheric intracerebral hemorrhage. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2019;119(8-2):46-52. doi: 10.17116/jnevro201911908246 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit81"><label>81</label><citation-alternatives><mixed-citation xml:lang="ru">Boluijt J, Meijers JCM, Rinkel GJE, Vergouwen MDI. Hemostasis and fibrinolysis in delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage: a systematic review. J Cereb Blood Flow Metab. 2015;35(5):724-33. doi: 10.1038/jcbfm.2015.13</mixed-citation><mixed-citation xml:lang="en">Boluijt J, Meijers JCM, Rinkel GJE, Vergouwen MDI. Hemostasis and fibrinolysis in delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage: a systematic review. J Cereb Blood Flow Metab. 2015;35(5):724-33. doi: 10.1038/jcbfm.2015.13</mixed-citation></citation-alternatives></ref><ref id="cit82"><label>82</label><citation-alternatives><mixed-citation xml:lang="ru">McGirt MJ, Lynch JR, Blessing R, et al. Serum von Willebrand factor, matrix metalloproteinase-9, and vascular endothelial growth factor levels predict the onset of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurgery. 2002;51(5):1128-34. doi: 10.1227/01.NEU.0000031751.23324.38</mixed-citation><mixed-citation xml:lang="en">McGirt MJ, Lynch JR, Blessing R, et al. Serum von Willebrand factor, matrix metalloproteinase-9, and vascular endothelial growth factor levels predict the onset of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurgery. 2002;51(5):1128-34. doi: 10.1227/01.NEU.0000031751.23324.38</mixed-citation></citation-alternatives></ref><ref id="cit83"><label>83</label><citation-alternatives><mixed-citation xml:lang="ru">Giovannoni G, Thorpe JW, Kidd D, et al. Soluble E-selectin in multiple sclerosis: raised concentrations in patients with primary progressive disease. J Neurol Neurosurg Psychiatry. 1996;60(1):20-6. doi: 10.1136/jnnp.60.1.20</mixed-citation><mixed-citation xml:lang="en">Giovannoni G, Thorpe JW, Kidd D, et al. Soluble E-selectin in multiple sclerosis: raised concentrations in patients with primary progressive disease. J Neurol Neurosurg Psychiatry. 1996;60(1):20-6. doi: 10.1136/jnnp.60.1.20</mixed-citation></citation-alternatives></ref><ref id="cit84"><label>84</label><citation-alternatives><mixed-citation xml:lang="ru">Noubade R, del Rio R, McElvany B, et al. Von-Willebrand factor influences blood brain barrier permeability and brain inflammation in experimental allergic encephalomyelitis. Am J Pathol. 2008;173(3):892-900. doi: 10.2353/ajpath.2008.080001</mixed-citation><mixed-citation xml:lang="en">Noubade R, del Rio R, McElvany B, et al. Von-Willebrand factor influences blood brain barrier permeability and brain inflammation in experimental allergic encephalomyelitis. Am J Pathol. 2008;173(3):892-900. doi: 10.2353/ajpath.2008.080001</mixed-citation></citation-alternatives></ref><ref id="cit85"><label>85</label><citation-alternatives><mixed-citation xml:lang="ru">Спирин НН, Спирина НН, Бойко АН. Фактор фон Виллебранда и молекулы адгезии у пациентов с рассеянным склерозом. Журнал неврологии и психиатрии им. С.С. Корсакова. 2014;114(2-2):35-9.</mixed-citation><mixed-citation xml:lang="en">Spirin NN, Spirina NN, Boiko AN. Von Willebrand factor and adhesion molecules in patients with multiple sclerosis. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2014;114(2-2):35-9 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit86"><label>86</label><citation-alternatives><mixed-citation xml:lang="ru">Saenz-Cuesta M, Osorio-Querejeta I, Otaegui D. Extracellular Vesicles in Multiple Sclerosis: What are They Telling Us? Front Cell Neurosci. 2014;8:100. doi: 10.3389/fncel.2014.00100</mixed-citation><mixed-citation xml:lang="en">Saenz-Cuesta M, Osorio-Querejeta I, Otaegui D. Extracellular Vesicles in Multiple Sclerosis: What are They Telling Us? Front Cell Neurosci. 2014;8:100. doi: 10.3389/fncel.2014.00100</mixed-citation></citation-alternatives></ref><ref id="cit87"><label>87</label><citation-alternatives><mixed-citation xml:lang="ru">Lu K, Liu L, Xu X, et al. ADAMTS13 ameliorates inflammatory responses in experimental autoimmune encephalomyelitis. J Neuroinflammation. 2020;17(1):67. doi: 10.1186/s12974-020-1713-z</mixed-citation><mixed-citation xml:lang="en">Lu K, Liu L, Xu X, et al. ADAMTS13 ameliorates inflammatory responses in experimental autoimmune encephalomyelitis. J Neuroinflammation. 2020;17(1):67. doi: 10.1186/s12974-020-1713-z</mixed-citation></citation-alternatives></ref><ref id="cit88"><label>88</label><citation-alternatives><mixed-citation xml:lang="ru">Ziliotto N, Bernardi F, Jakimovski D, et al. Hemostasis biomarkers in multiple sclerosis. Eur J Neurol. 2018;25(9):1169-76. doi: 10.1111/ene.13681</mixed-citation><mixed-citation xml:lang="en">Ziliotto N, Bernardi F, Jakimovski D, et al. Hemostasis biomarkers in multiple sclerosis. Eur J Neurol. 2018;25(9):1169-76. doi: 10.1111/ene.13681</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
